Active Ingredient History

NOW
  • Now
Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a US National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. Later it was discovered that endophytic fungi in the bark synthesize paclitaxel. When it was developed commercially by Bristol-Myers Squibb (BMS), the generic name was changed to paclitaxel and the BMS compound is sold under the trademark Taxol. In this formulation, paclitaxel is dissolved in Kolliphor EL and ethanol, as a delivery agent. Taxol is marketed for the treatment of Breast cancer; Gastric cancer; Kaposi's sarcoma; Non-small cell lung cancer; Ovarian cancer. A newer formulation, in which paclitaxel is bound to albumin, is sold under the trademark Abraxane. Paclitaxel is a taxoid antineoplastic agent indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast cancer. Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis. Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer. Paclitaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, paclitaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, paclitaxel binds to the β subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of paclitaxel locks these building blocks in place. The resulting microtubule/paclitaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that paclitaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function.   NCATS

  • SMILES: CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@@H]4[C@@]5(CO[C@@H]5C[C@H](O)[C@@]4(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C6=CC=CC=C6)C7=CC=CC=C7
  • InChIKey: RCINICONZNJXQF-MZXODVADSA-N
  • Mol. Mass: 853.9061
  • ALogP: 3.74
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)

United States

$0.5358 - $899.7100

Australia

$3.8532 - $266.1372
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

130-nm albumin-bound paclitaxel | (2ar-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1h-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester | 5beta,20-epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2r,3s)-n-benzoyl-3-phenylisoserine | abi-007 | abraxane | albumin-bound paclitaxel | ang1005 | bavituximab plus paclitaxel | bms-181339-01 | capxol | carboplatin and paclitaxel | ct2103 | ct-2103 | cyclopax | dha-paclitaxel | docosahexaenoic acid-paclitaxel | docosahexaenoyl-paclitaxel | ebetaxel | endotag-1 | gemcitabine - nabpaclitaxel | genaxol | grn1005 | grn 1005 | ig-001 | liposomal paclitaxel | mitotax | nabpaclitaxel | nab paclitaxel | nab-paclitaxel | paclical | paclitaxe | paclitaxel | (-)-paclitaxel | paclitaxel-angiopep-2 conjugate | paclitaxel docosahexaenoic acid | paclitaxel-loaded polymeric micelle | paclitaxel nanoparticle albumin bound | paclitaxel poliglumex | paclitaxel polyglumex | padexol | paxene | paxlitaxel | peg-paclitaxel | pg-txl | plaxicel | polyglutamic acid-paclitaxel | poly(l-glutamic acid)-paclitaxel | ppx paclitaxel cpd | sor007 | sparc1210 | sparc1507 | taxane | taxol | taxol 100 | taxol a | taxoperxin | taxoprexin | tocosol paclitaxel | xyotax

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue